Compare PBYI & RMM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PBYI | RMM |
|---|---|---|
| Founded | 2010 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 263.4M | 285.6M |
| IPO Year | 2011 | 2019 |
| Metric | PBYI | RMM |
|---|---|---|
| Price | $7.61 | $14.31 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $7.00 | N/A |
| AVG Volume (30 Days) | ★ 370.3K | 62.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 37.78 | N/A |
| EPS | ★ 0.35 | N/A |
| Revenue | ★ $27,685,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $21.94 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.58 | $12.55 |
| 52 Week High | $7.68 | $15.23 |
| Indicator | PBYI | RMM |
|---|---|---|
| Relative Strength Index (RSI) | 69.82 | 58.17 |
| Support Level | $6.32 | $13.82 |
| Resistance Level | N/A | $14.88 |
| Average True Range (ATR) | 0.29 | 0.20 |
| MACD | 0.07 | -0.03 |
| Stochastic Oscillator | 93.89 | 43.75 |
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
RiverNorth Managed Duration Muni Inc Fd is a United States based diversified, closed-end management investment company. Its primary investment objective is current income exempt from regular U.S. federal income taxes. The Fund's secondary investment objective is total return.